Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study

Abroad (travel likely)Recruiting

Conditions

Carcinoma, Hepatocellular · Neoplasms, Glandular and Epithelial · Adenocarcinoma · Digestive System Neoplasms · Liver Neoplasms

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Minjie Yang) · yang.mingjie@zs-hospital.sh.cn · +86 02164041990

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors

Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer) · Pancreatic Ductal Adenocarcinoma (PDAC) · Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE1

Beijing, China · Beijing, China

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Colorectal Carcinoma · Endometrial Carcinoma · Melanoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States · Los Angeles, United States

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Cancer · Breast Cancer · Non-Small Cell Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beijing, China

Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Abroad (travel likely)Recruiting

San Antonio, United States